Status:
UNKNOWN
Deep Learning in Retinoblastoma Detection and Monitoring.
Lead Sponsor:
Beijing Tongren Hospital
Conditions:
Retinoblastoma
Eligibility:
All Genders
Up to 5 years
Brief Summary
Retinoblastoma is the most common eye cancer of childhood. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment. In the curr...
Detailed Description
Retinoblastoma, the most common eye cancer of childhood, affects 1 in 15 000 to 1 in 18 000 live births. China has the second-largest number of patients with retinoblastoma in the world. Eye-preservin...
Eligibility Criteria
Inclusion
- Retinoblastoma patients undergo standard medical management.
Exclusion
- The operators identified images non-assessable for a correct diagnosis, due to reasons such as blur and defocus, and excluded them from further analysis.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05308043
Start Date
March 1 2020
End Date
October 1 2022
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wen-Bin Wei
Beijing, Beijing Municipality, China, 100730